P16-5 (Lo5) GROUPWORK (EPS with Complex Capital Structure) Amy Dyken, controller at Fitzgerald Pharmace re for Fitzgerald's financial statements. Below is selected financial information for the fiscal year ended June 30, 2017 austries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related dis FITZGERALD PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% 8% convertible bonds payable 10% bonds payable $ 1,000,000 5,000,000 6,000,000 $12,000,000 Total long-term debt Shareholders' equity Preferred stock, 6% cumulative, $50 par value, 100,000 shares authorized, 25,000 shares issued and outstanding s 1,250,000 Common stock, $1 par, 10,000,000 shares authorized, 1,000,000 4,000,000 6,000,000 $12,250,000 1,000,000 shares issued and outstanding Additional paid-in capital Retained earnings Total shareholders' equity The following transactions have also occurred at Fitzgerald 1. Options were granted on July 1, 2016, to purchase 200,000 shares at $15 per share. Although no options were exercise during fiscal year 2017, the average price per common share during fiscal year 2017 was $20 per share. 2. Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,00 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2016. 3. The preferred stock was issued in 2016. 4. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2017. 5. The 1,000,000 shares of common stock were outstanding for the entire 2017 fiscal year 6. Net income for fiscal year 2017 was $1,500,000, and the average income tax rate is 40%. Instructions For the fiscal year ended June 30, 2017, calculate the following for Fitzgerald Pharmaceutical Industries (a) Basic earnings per share. (b) Diluted earnings per share